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Abstract
The high rates of failure in oncology drug clinical trials highlight the problems of using pre-clinical data to predict the
clinical effects of drugs. Patient population heterogeneity and unpredictable physiology complicate pre-clinical cancer
modeling efforts. We hypothesize that gene networks associated with cancer outcome in heterogeneous patient
populations could serve as a reference for identifying drug effects. Here we propose a novel in vivo genetic interaction
which we call ‘synergistic outcome determination’ (SOD), a concept similar to ‘Synthetic Lethality’. SOD is defined as the
synergy of a gene pair with respect to cancer patients’ outcome, whose correlation with outcome is due to cooperative,
rather than independent, contributions of genes. The method combines microarray gene expression data with cancer
prognostic information to identify synergistic gene-gene interactions that are then used to construct interaction networks
based on gene modules (a group of genes which share similar function). In this way, we identified a cluster of important
epigenetically regulated gene modules. By projecting drug sensitivity-associated genes on to the cancer-specific inter-
module network, we defined a perturbation index for each drug based upon its characteristic perturbation pattern on the
inter-module network. Finally, by calculating this index for compounds in the NCI Standard Agent Database, we significantly
discriminated successful drugs from a broad set of test compounds, and further revealed the mechanisms of drug
combinations. Thus, prognosis-guided synergistic gene-gene interaction networks could serve as an efficient in silico tool
for pre-clinical drug prioritization and rational design of combinatorial therapies.
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Introduction
The development of effective cancer drugs is a particularly
challenging problem, and selection of appropriate preclinical
cancer models has emerged as a key factor affecting successful
oncology drug discovery and development [1]. There are multiple
examples of drug candidates that showed promise in the pre-
clinical stage but which then failed to demonstrate benefits in
clinical trials. EGFR- and VEGF-blocking combo are recent
examples of drugs which ultimately produced disappointing results
after encouraging pre-clinical results [2]. One of the commonly
accepted reasons is that the targeted therapies provide benefit only
to a subset of patients who have the appropriate genetic changes in
their cells; for example, Herceptin (trastuzumab) shows efficacy
only in HER2-positive breast cancers [3]. Thus the key to success
in the clinical stage may depend strongly on precise selection of
target populations.
In the modern drug discovery pipeline, assessments of the
efficacy and toxicity of therapeutic agents are based on relatively
homogeneous cell or animal models, and the heterogeneity issue is
only encountered once the most expensive clinical trials are
underway in human subjects. The poor success rate of oncology
drug development suggests that the standard preclinical cancer
models are failing to predict how the drug candidate works in
clinical trials [4]. Furthermore, recent results from comprehensive
genomic efforts such as The Cancer Genome Atlas (TCGA) have
highlighted the marked heterogeneity of genetic alterations in
patient populations [5]. It suggests that the intrinsic heterogeneity
in genetic and/or epigenetic alterations which are driving the
tumorigenesis might be one of the main causes for the observed
discrepancies between clinical trials and standard pre-clinical
models. Thus, efforts to establish new cancer animal models which
mimic heterogeneous patient populations might be even more
challenging than initially realized [1,4].
Nevertheless, several promising new paradigms in cancer
drug development have recently been introduced of which
Network Pharmacology and Synthetic Lethality seem to hold
particular promise. Network Pharmacology attempts to model
the effects of a drug action by simultaneously modulating mul-
tiple proteins in a network [6,7]. However, this approach still
faces a number of challenges. In particular, the absence of
cancer-specific functional gene/protein networks and the lack of
further characterization of the network behavior (e.g, network
robustness [8] under perturbation) makes it difficult to design
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refers to a specific type of genetic interaction between two genes,
where mutation of one gene is viable but mutation of both
leads to death [10]. It has already been demonstrated that this
concept can be exploited to develop a therapeutic strategy. For
example, by using an inhibitor targeted to a Poly(ADP-Ribose)
Polymerase (PARP) that is synthetically lethal to a cancer-specific
mutation (BRCA), researchers could target cancer cells to achieve
antitumor activity in tumors with the BRCA mutation[11].
However, because of the difficulties of systematically identifying
in vivo synthetic lethal genes in human individuals, current high
throughput Synthetic Lethality screening is limited to only in
vitro cell lines [12].
Transcriptome profiles of heterogeneous patient populations
have been comprehensively sampled by high throughput gene
expression microarrays in ongoing prognosis studies (the original
motivation being to identify gene expression signatures for
prognostic or predictive biomarkers) [13]. Recognizing this, we
propose that this kind of patient prognosis data could be used to
help prioritize drug candidates or drug combinations at the pre-
clinical stage. To test the feasibility of this hypothesis, we
combined microarray gene expression data with cancer prognostic
information to identify cancer-specific gene-gene interactions. We
achieved this by defining a set of ‘gene modules’ and then used the
microarray data to identify cancer specific gene interactions that
occurred between genes in different modules. A single gene
module represented a list (as opposed to a network) of genes that
shared a similar function or regulatory mechanism and was
defined as one of the following four collections: (1) a group of genes
in a protein-protein interaction network or protein complex; (2) a
set of genes sharing a common function annotation in the Gene
Ontology; (3) a set of genes which are involved in the same
pathway; (4) a set of genes which are governed by a common
regulation mechanism. i.e., targets of the same microRNA. The
gene interactions were identified by using an information theoretic
measure of synergy[14] based on the microarray expression data.
Two genes that are identified to be synergistically related form a
‘‘Synergistically Inferred Nexus’’ (SIN). These SINs together form
an inter module network where the nodes in the constructed
network represent functional gene modules, and links between two
nodes represent interactions between modules. We found that the
constructed network contained a number of highly connected
nodes and, given the potential pivotal role of the associated
modules in affecting patient outcome, we named them ‘gatekeeper’
modules. Furthermore, by examining their associated GO terms,
we found that drug accessibility, microenvironment and immune system
regulation are common themes in the gatekeeper modules identified
from multiple types of human cancers.
Finally, by projecting drug sensitivity-associated genes on to
the cancer-specific inter-module network, we defined a ‘perturba-
tion index’ to quantify the potential efficacy of drugs in terms
of the drugs’ perturbation pattern on the inter-module network
(see Methods). We demonstrated that this index could success-
fully discriminate drugs from candidate pools (i.e., drug candi-
dates in the NCI Standard Agent Database, see Methods).
With this approach, we have illustrated an objective way to
quantify the synergistic effects of drug combinations, and the
rationale of combinatorial perturbations on these intrinsic co-
operation networks. Thus, the integration of action data
(describing the effect of a drug acting on a cell) with an intrinsic
gene network (derived from a patient population) not only
provides a novel in silico prioritization tool in the early preclinical
stage, but can also suggest a potential treatment strategy based on
the gene networks.
Results
The framework of in silico modeling
The basic framework of our modeling method is illustrated in
Figure 1a. There are three independent components in the
method: (1) construction of gene modules; (2) identification of
disease-specific gene-gene interactions from patient gene expres-
sion and prognosis data; (3) identification of drug sensitivity
associated genes.
A key step in the method is the identification of gene-gene
functional interactions as synergistic events; these events are
determined not only by gene expression data but also by prognosis.
The proposed in vivo genetic interaction which we call ‘synergistic
outcome determination’ (SOD) is a concept similar to ‘Synthetic
Lethality’ [10]. SOD is defined as the synergy of a gene pair with
respect to cancer patients’ outcome, whose correlation with
outcome is due to cooperative, rather than independent, contribu-
tions of genes (see Methods). Identification of a synergistic gene
pair leads to the creation of a Synergistically Inferred Nexus (SIN)
which, when combined with other SINs, produces an Inter-Module
Cooperation Network (IMCN). An important distinction between
our method and the concept of Synthetic Lethality is that in the
latter the phenotype is defined at the cell-level (i.e. cell death),
whereas we define the phenotype at the physiological level (i.e. the
survival outcome of the individual). Furthermore, the gene
expression profiling data for a tumor is from a mixture of tissues
which include epithelial cells and other cells in the microenviron-
ment; thus a SIN captures events at the tissue level rather than at
the cell level. This also leads to differences in the interpretation of
the constructed network. In Synthetic Lethality, the nodes
represent individual genes, but we use a gene module as the
principal unit and thus capture a higher level inter-module of
cooperation. We mapped a list of genes onto a set of gene modules
according to a comprehensive range of functional data based on
currently available sources (the gene function annotation database,
protein network and protein complexes, annotated pathways, and
genes co-regulated by microRNA, Figure 1a and Methods). The
reasons for capturing module level cooperation rather than
considering the interactions between individual genes were as
follows: (1) a gene module (or corresponding ‘gene set’) is a more
appropriate representation of the functionality of the system, which
occurs as a series of interactions between elements. It is widely
accepted that one shortcoming of microarray prognosis experi-
ments is the low reproducibility. It often leads to completely
different prognosis-associated gene signatures based on different
patient cohorts. Considering that the subnetwork marker extracted
from protein interaction databases are more reproducible than
individual gene markers [15,16], we assume that the identification
of module-module interactions is more robust than that of gene-
gene interactions. For example, if the interaction between gene
modules A1 and B1 (in Figure 1c) is true, then many of the genes
in gene module A1 could interact with a many of the genes in
module B1. The robust identification of individual gene-gene
interactions between A1 and B1 is harder, because it is possible that
different set of B1 genes will be identified as interacting with A1
genes when different patient cohorts or microarray datasets are
examined (Figure 1c); (2) Multiple genes within a gene module
might have redundant functionality, and a tumor could exploit
alternative pathways or mechanisms within a gene module to
develop drug resistance [17,18]. Since therapeutic intervention
targeting different yet functionally redundant genes within a gene
module might be equivalent, it is important to highlight a drug
perturbation pattern on an inter-module rather than an intra-
module network.
Network Based Drug Screening
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interrogate the action of compounds on cells. The first method,
adopted by the Connectivity Map [19] effort, measures a
‘compound response signature.’ In this approach gene expression
signatures are established based on changes in gene expression in
response to short term treatment with particular compounds; this
response signature can serve as an effective tool for probing the
compound(s) mechanism of action (MOA) [19]. A second method
is measurement of a ‘drug sensitivity signature’ and is used by
various applications based on the National Cancer Institute NCI
60 in vitro drug screen project [20]. The NCI 60 cell lines screen
panel has proved to be an effective way to identify drug sensitivity
specific biomarkers [21] as the panel has already been compre-
hensively characterized via profiling at different levels (mRNA,
protein, microRNAs, DNA methylation and metabolites etc.).
To incorporate the data describing the perturbation effects of
drug compounds we constructed cancer specific inter-module
cooperation networks based around the identified gene modules
Figure 1. The proposed schema for compound Pattern of Action (POA) analysis. a. The workflow of POA analysis, which relies on
converging two lines of information: the intrinsic module structure which cooperatively determine the clinical prognosis outcome of heterogeneous
patient population (blue rectangles); and the gene signatures for compound sensitivity resulting from in-vitro cell line screen (pink rectangles). b.
Illustration of the ‘synergistic outcome determination’ (SOD), a proposed in vivo gene-gene functional interaction. SOD is defined as the synergy ofa
gene pair with respect to cancer patients’ outcome. Here gene A and gene B have two states: high expression or low expression level. Red triangles
represent ‘bad outcome’ patients (shorter survival time or metastasis), and green rectangles represent ‘good outcome’ patients (longer survival time
or non metastasis). In combination, the two genes are sufficient to determine the patient outcome, but each of them individually is uncorrelated with
patient outcome. For example, given gene A state as ‘low expression’, all patients with A(Low) are distributed in two clusters and thus insufficient to
determine the patients outcome. Given combination of A and B state, i.e., A(Low) B(high), its sufficient to determine the patient outcome as ‘good
outcome’. c. Inter-module cooperation network construction. For each gene (g1,g4 at left) in a given gene module, we identify their synergistic
partner genes (the link from gene in module A1 to gene module B1 form a ‘Synergistically Inferred Nexus’, see Methods). Then the gene modules
which are over-represented in the resulting gene list are identified as the ‘cooperative modules’ corresponding to the query gene module. d.
Compound perturbation pattern. Genes associated with compound sensitivity (nodes within blocks) might be topologically cross-linked to the
functional pathway (red rectangles) induced by compound perturbation. e. Disease specific inter-module cooperation network, nodes represent
gene modules and the direct link represents the relationship between the ‘query module’ (A1) and its ‘cooperative module’ (B1). Here B1 cooperates
with a large number of modules (with flow-in links), thus we called this special class of modules ‘gatekeeper modules’ (B1, B2) and others (without
flow-in links) as ‘checkpoint modules’ (A1–A5). f. The Pattern of Action (POA) of one candidate compound generated by overlapping the disease-
specific inter-module network (e) with the module hits by sensitivity-associated genes (d).
doi:10.1371/journal.pone.0013937.g001
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microarray gene expression data and prognosis information
(Figure 1e and Methods). This inter-module network allowed
us to mine the drug action pattern by incorporating drug-gene
relationships. To represent the characteristic pattern of drug
action on cells, we chose the genes that were significantly
associated with drug sensitivity across NCI 60 cell lines (drug-
gene association [21], see Methods). As illustrated in Figure 1d,
although these genes may not be directly linked to the primary
drug targets (i.e. the mechanism of action), they should be close to
the pathway in which the targets are involved. Thus these drug
sensitivity associated genes can indicate the key pathways
associated with drug efficacy [21] and the overlap of sensitivity
associated genes (Fig. 1d) with the baseline inter-module network
(Fig. 1e) could highlight the characteristic compound perturba-
tion pattern, which we call the Pattern of Action (POA, Fig. 1f).
For simplicity, the genes which were significantly correlated with
compound(s) sensitivity across 60 cell lines were selected
(Methods)a n da r er e fe rr e dt oa sc o mp o u n dg e n e‘ h i t s ’i nt h i sr e p o rt .
Inter-module networks associated with prognosis
outcome
If two genes A and B could synergistically determine or predict
prognosis outcome (form a SIN), we call B a synergistic partner of
A (or vice versa). By enumerating all genes in a gene module and
identifying their synergistic partners, followed by further identify-
ing the enriched gene modules within these partners (Supporting
Text S1), the inter-module network was first constructed for a
patient population of non-small cell lung carcinoma (NSCLC), a
major type of lung cancer. To get a more specific view of the
constructed networks, we illustrate a network hit by Cisplatin (the
first line treatment option for NSCLC) in Figure 2a.
Analysis of the inter-modules network obtained from three other
types of cancer (breast cancer, ovarian cancer and leukemia, see
Supporting Text S1), also identified common features shared
between these networks. Specifically, there exist several hub nodes
which have a large number of flow-in links, indicating they play a
central role in determining the clinical outcome. We named these
highly connected influx nodes ‘gatekeeper modules’ and other
outflux nodes as ‘checkpoint modules’.
Figure 2b illustrates the high connectivity of the gatekeeper
modules. In the intrinsic network for lung cancer (NSCLC), a
small set of gatekeeper modules cooperate with a large number of
modules (in terms of outcome prediction). The largest identified
hub was ‘BP: complement activation, classic pathway’ which,
according to the Gene Ontology biological process definition, has
cooperation with 567 checkpoint modules. This high connectivity
was evident in all the four types of cancers we studied as there was
significant overlap amongst most of the gatekeeper modules (see
Figure S1 for gatekeeper modules of breast cancer, ovarian
cancer and leukemia).
Based on this analysis, the biological themes of the most highly
connected gatekeeper modules in multiple types of cancer are
summarized in Figure 2c, and comprise 3 major themes: (1) drug
accessibility to tumor cells (drug absorption/metabolism/delivery),
(2) tumor microenvironment and (3) immune regulation (also a key
component of the tumor microenvironment). These common
themes indicate the pivotal role of the in vivo tumor microenviron-
ment, and the efficacy of drugs could be regulated by these
components (Figure 2c). For example, the control of drug
accessibility to tumor cells by increasing the efflux of the drug
molecules (multidrug resistance) is a major factor in the failure of
multiple forms of chemotherapy [22]. Furthermore, the most
common gatekeeper module identified is ‘BP: complement
activation, classic pathway’, which plays a pivotal role in the ‘fine
tuning’ of both the innate and cognate immune responses [23];
there is evidence that shows a tumor could exploit the complement
activation to set up an immunosuppressive microenvironment,
thereby gaining a growth advantage [24].
Considering the increased recognition of the complexity of
tumor regulation in vivo, the difficulty of identifying effective cancer
cures (as evidenced by drug resistance) may be a consequence of
the robustness of physiology-level (or microenvironment-level)
network regulation [8]. Our results suggest characterization of this
cooperation network and the potential co-opt strategies which the
tumor may exploit will aid in the development of new strategies to
efficiently disrupt the highly robust network established by the
tumor.
Association of gatekeeper modules with genetic and
epigenetic aberration events
To characterize the intrinsic features of an inter-module
network, particularly the identification of ‘gatekeeper modules’,
we further compared the rates of genetic (somatic mutation) and
epigenetic (DNA methylation) aberration on tumor vs. normal
tissues. For each type of module, we selected genes which were
identified as being highly used (i.e. one gene involved in multiple
gene modules) as representative of the whole set (Methods).
Results for the lung cancer (NSCLC) IMCN show that gatekeeper
modules have a significantly lower incident rate of somatic gene
mutation, but a notably higher incident rate of DNA methylation
aberration (Figure 3a). All other types of cancers studied show a
similar pattern (data not shown). Current strategies to treat cancer
is mainly driven by identifying genetic changes (e.g., EGFR,
epidermal growth factor mutations in lung cancer), but recent
evidence suggests that epigenetic plasticity together with genetic
lesions also drives tumor progression [25,26]. Our data indicates
most genes involved in gatekeeper modules frequently undergo
epigenetic aberration during cancer, supporting the role of
epigenetic lesions in tumor phenotype.
Contribution of various evidence sources for gene
module definition
Our gene modules were generated by integrating multiple large
scale evidence of gene function categorizations such as protein-protein
interaction networks, gene annotation databases, and microRNA
target genes. To analyze the contribution from different evidence
sources to the IMCN, we summarized the evidence sources in all gene
modules of the lung cancer (NSCLC)n e t w o r k( Figure 3b). The other
three types of cancers studied showed a similar pattern (data not
shown). The top contribution was from protein-protein interaction
subnetworks (47%) which were identified by simply fetching the
neighboring proteins of hub nodes in a physical protein interaction
network (Methods). Clearly, a more comprehensive decomposition
of the modularity and community structures within a protein
interaction network will provide a more extensive result set, given
the large amounts of methodology and data from related systems
biology studies [27]. It was not unexpected to see that the Gene
Ontology, as a hierarchical knowledge representation system, made a
major contribution to the definition of the gene modules (e.g.
biological process category contributes 13%). However, it was more
surprising to see that microRNAs modules made a similarly significant
contribution of 16%, given these modules were defined by predicted
microRNA target genes collected in the mirBase database [28].
Perturbation index and validation
Based on the above characterization of the intrinsic features of
the inter-module cooperation network, we hypothesized that the
Network Based Drug Screening
PLoS ONE | www.plosone.org 4 November 2010 | Volume 5 | Issue 11 | e13937Figure 2. Topological characteristics of the Pattern of Action network. a. Gatekeeper modules and checkpoint modules, demonstrated by
an example (the POA result of Cisplatin on non-small cell lung carcinoma). We define the flow-out nodes (blue circles) as ‘checkpoint modules’ (from
Network Based Drug Screening
PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e13937potential efficacy of drug intervention relies on its perturbation
pattern on this network (Figure 4a). For a drug designed to
perturb genetic aberrations (checkpoint modules), the key to
success is whether it simultaneously perturbs the corresponding
gatekeeper modules which cooperatively determine the outcome
with the former. Thus there are two key factors in determining the
extent of perturbation on the cooperation network: (1) the number
of gene hits in gatekeeper modules and (2) the number of active
links between gatekeeper modules and checkpoint modules
(meaning simultaneous hits on gatekeeper modules and their
linked checkpoint modules). As a measure of these quantities we
defined the perturbation index (PI) as the summation of these two
factors followed by appropriate normalization by the total number
of gene hits (see Methods).
To assess the potential application of this approach for
prioritizing compounds for clinical trials (based on the information
available in pre-clinical stage), we studied a subset of compounds
defined in the ‘Standard Agent Database’, originally created by Boyd
[29] and ultimately finalized by the NCI. The selection criteria
was compounds which have been submitted to the FDA for review
as a New Drug Application, as well as compounds that have
reached a particular high stage of interest at the NCI. For each
type of cancer, we divided this compound list into two parts: FDA
approved and routinely used drugs (the Successful drug list) and
the remainder (the Candidate list), and tested whether we could
statistically discriminate between these two compound lists using
the perturbation index.
A bootstrapping-based method showed that the PI of successful
compounds is significantly higherthan thecorrespondingPIsforthe
candidate list in lung cancer (NSCLC) (p-value 0.01, Figure 4c).
Because our perturbation index definition is highlighting the
importance of gatekeeper modules, we also calculated a different
measure of the perturbation index which is based on the number of
gene hits in checkpoint rather than gatekeeper modules, multiplied
by the number of active links, as a control. The result demonstrated
that this modified index cannot achieve significant discrimination
(Figure 4d), which confirmed the unique role of gatekeeper
modules in drug efficacy. When we further removed the
information contribution from active links and only counted the
gatekeeper module hits, it turned out that there was a partial loss in
discriminative power although the difference was still significant (p-
value 0.04, Figure 4e). Finally, much poorer performance was
achieved when a count based on only checkpoint module hits was
used (Figure 4f). Our results also showed that the perturbation
index is independent of the total number of gene hits for each
compound and other parameters (see Figure S2, S3, S4, S5, S6,
S7, S8, S9). In summary, the results demonstrate the effectiveness
of the perturbation index, and confirm that the key factors which
account for drug efficacy are primarily the hits on gatekeeper
modules; and additionally, this could be further influenced by the
‘active’ control scope of the gatekeeper modules.
Rationale and synergy quantification of drug
combination
Having established the validity of the perturbation index we
then estimated it for lung cancer (NSCLC) drugs and related
targeted agents in clinical development (Figure 5a). The first line
treatment drug Cisplatin achieved a rank of two (PI=21.09, see
Figure 2a for the Pattern of Action for Cisplatin). In the
simulation of two-agent combinations, Bortezomib, the proteo-
some inhibitior, gained the largest number of benefits when
combined with other agents (Erlotinib, Paclitaxel, Rapamycin,
Etoposide, Gefitinib and Gemcitabine, Figure 5b), suggesting a
multifaceted potential in combinatory treatment.
As a successful drug for treating multiple myeloma, Bortezomib
is also being studied in the treatment of other types of cancer
(There are 189 Bortezomib related clinical trials to date according
to the NCI website: www.cancer.gov). The interference with
ubiquitin pathways, which labels proteins for degradation by the
proteasome, has proved to be a valid strategy for the development
of anticancer drugs [30]. In a RNA interference (RNAi)-based
synthetic lethal screen seeking paclitaxel chemosensitizer genes in
a human NSCLC cell line, proteasome is the most enriched gene
group [12]. Recently, a phase II clinical trial reported notable
survival benefits in lung cancer (NSCLC) patients using a
Bortezomib plus Gemcitabine/Carboplatin combination as first-
line treatment [31]. In line with the above result, here we
identified the combinatory benefits of both the Bortezomib-
Paclitaxel and Bortezomib-Gemcitabine combos (Figure 5b).
Impressively, in the intrinsic inter-module network, the gene
modules ‘UBQLN4 (ubiquilin 4) subnetwork’ shared synergy with
360 gene modules (Figure 2b).
Taking Bortezomib-Bemcitabine as an example, we further
studied the mechanism of drug combination benefits. Compared
to the chemotherapy agent Gemcitabine (Figure 5c), the Pattern of
ActionforBortezomibshowsamorefocusedhitpattern(Figure5d).
For the gatekeeper module hit pattern, Bortezomib has relatively
more hits on the ‘UBQLN4 (ubiquilin 4) subnetwork’, and shows a
very strong association with the ‘MMP2 (matrix metallopeptidase)
subnetwork’ and ‘digestion’, which are targeted less frequently by
Gemcitabine. As matrix metallopeptidases play an important
regulatory role in the ubiquitylation pathway [32], the synergistic
benefit of the Bortezomib-Gemcitabine combo in bladder tumors is
related to matrix metalloproteinases and other microenvironment
factors [33]. In terms of checkpoint modules, Bortezomib also has
more gene hits on microRNA target modules has-mir-301a,w h i c hi s
revealed as a human embryonic stem cell-specific microRNA [34].
The results for our initial design for the mechanism of drug
combination synergy (Figure 1e) confirmed the proposed
rationale: Gemcitabine serves as a drug establishing a baseline
perturbation on the inter-module network, but Bortezomib could
add a more focused perturbation on key gatekeeper modules
which are linked to the checkpoint perturbation established by
Gemcitabine (Figure 5d). Knowledge of a drug’s mechanism of
action is critical for successful optimization of therapeutic drugs,
especially for rational design of drug combinations. Our models
could serve as a powerful tool for generating testable hypotheses
on the mechanism of synergistic drug combinations. For example,
our result suggests that the MMP2 subnetwork might be one of the
key gene modules which are involved in the synergy between
Gemcitabine and Bortezomib (Figure 5d). If this hypothesis could
gene signatures of drug sensitivity), and the flow-in nodes (red circles) as ‘gatekeeper modules’ (which cooperate with a large number of modules to
determine the clinical prognosis outcome). The radius of the red circles is proportional to the in-degree (number of flow-in links) of the node in the
generic inter-module cooperation network. b. All of the ‘gatekeeper’ modules in a generic inter-module cooperation network generated for lung
cancer (non-small cell lung carcinoma). The length of bars and annotated numbers indicate in-degree (number of flow-in links) for each gatekeeper
module (y-axis). c. An ensemble of common gatekeeper modules in multiple cancer types highlights a physiology-level ‘pathway’ of drug action.
Gene module names start with a 2-character header that indicates the gene module definition source, PN: protein subnetwork; PA: pathway; BP: Gene
Ontology biological process; MF: Gene Ontology molecular function; CC: Gene Ontology cellular component; MR: microRNA targets.
doi:10.1371/journal.pone.0013937.g002
Network Based Drug Screening
PLoS ONE | www.plosone.org 6 November 2010 | Volume 5 | Issue 11 | e13937Figure 3. Biological function characterization of the inter-module cooperation network. a. For each type of module (gatekeeper and
checkpoint), the top 10% and 20% most highly used genes are used as the representative genes for each module, and their incident rate of somatic
mutation frequency and DNA methylation aberrant was calculated for lung cancer (NSCLC); p-value for incident rate difference was calculated using
the binomial distribution (see Methods). b. Contribution of various evidence sources for gene module definition in lung cancer (NSCLC). We
summarized the number of various types of gene module definitions in the identified inter-module network for lung cancer (NSCLC) and the
proportional contribution of various evidence sources for the gene modules were plotted.
doi:10.1371/journal.pone.0013937.g003
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could be proposed based on this assumption.
Discussion
The preclinical development process has been criticized for its
inability to identify drugs that are most likely to succeed in the
human clinic. Many attempts have been made to address this issue
by creating novel genetically engineered animal models for human
cancers [35]. However, creating novel animal models to mirror the
natural distribution of mutations is still a challenge, due in part to
heterogeneity and unknown mutations (i.e., structure aberrations),
which need to be revealed via ongoing efforts such as next
generation sequencing. In this context, in silico modeling or
simulations, which are based on the heterogeneous patient
populations, provide an alternative yet cost-effective way to identify
key factors affecting success rate in the human clinic. The modern
drug discovery and development process is mainly a forward (and
stepwise) approach: from drug target identification, preclinical
assessment and mechanism studies, towards clinical trials. The in
Figure 4. Principle and validation of perturbation index (PI). a. Perturbation index for single compound perturbation. According to our
definition of perturbation index (PI, see Methods), PI (drug 1) =3 (Three active links from A1, A2, A5 to B1), while PI (drug 2) =1 (one active link from
A3 to B1). b. The rationale of drug POA analysis applied to in silico drug combination assessment. If we assume one drug already has an established
action (primary drug at left), then for each candidate auxiliary drug (shown at right), the perturbation index is re-calculated after adding the additional
module hits provided by the secondary drug (see Methods). Here drug 1 is ‘‘better’’ than drug 2 because drug 1 has more active links (3 links from
A5, A2 and A4) with the primary drug. c. Perturbation index can be used to discriminate successful drugs against candidate compounds. We use a
bootstrap-based method to evaluate if the average PI of successful drugs against lung cancer (NSCLC) is significantly different from the candidate
compounds (see Methods). Blue line shows background distribution and the red line shows the average PI of successful drugs. We also considered
modified PI definitions and investigated their effect/contribution on the performance of PI. These modifications include: d. bootstrap result from
pseudo PI definition by using checkpoint modules information to replace gatekeeper modules information, e. bootstrap result from pseudo PI
definition by only using gatekeeper modules hits, and f. bootstrap result from pseudo PI definition by only using checkpoint modules hits.
doi:10.1371/journal.pone.0013937.g004
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PLoS ONE | www.plosone.org 8 November 2010 | Volume 5 | Issue 11 | e13937Figure 5. A proof-of-principle demonstration for a drug combination study based on POA analysis. a. Rank of drugs and agents in
clinical development for lung cancer (NSCLC) according to their perturbation index. Text after agent name indicates the mechanism of action. b. The
perturbation index of pair-wise combination of NSCLC agents. The widths of links between two drugs are proportional to their combined PI index
(see Methods), and red links indicates the potential benefit of the combination: PI (combination) . maximum (PI (drug 1), PI (drug 2)). c. POA of
gemcitabine, red (at right) circles represent all gatekeeper modules. For clarification, selected checkpoint modules (top number of gene hits) are
shown as blue (at left) circles. The size of circle is proportional to the number of gene hits for each module and the link widths are also proportional
to the number of gene hits from the source node (checkpoint modules). d. POA of bortezomib with same schema. Gene module names start with a
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between clinical trials to aid informed preclinical decisions.
Our analysis scheme has several unique characteristics as a
preclinical in silico modeling tool. Specifically these are: (1) mirroring
drug behavior on heterogeneous patient populations; (2) cost-
effectiveness: One of the key inputs for effective modeling is the
prognosis data, which is already available for large populations in
variouscancer types. Furthermore, this kind of retrospective study is
cheap and less time consuming; (3) flexibility: It is easy to integrate
the model with compound action mechanisms or patterns such as,
for example, the NCI 60 in vitro cell line screening data used in this
study. (4) extensibility: The pool of gene modules serves as a ‘library
of mechanisms’ to probe the intrinsic gene network, and the power
of the model can be sustainably improved along with emerging new
gene module definitions. The ongoing efforts on interrogating
genetic and epigenetic functional elements (e.g., the ENCODE
project [36]) will greatly enhance the available options for gene
modules definition and improve the resolution, specificity and
multi-faced coverage of biological processes. For example, our
analysis shows that microRNA regulated genes are very informative
data sources in terms of gene module definitions.
Theviewthatgenomicinstabilityisthekeyfactorintumorigenesis
and tumor progression has been the prevailing paradigm for many
years. Based on this, most of modern oncology drug discovery efforts
are targeting to the etiology of cancer by seeking the key genetic
lesions which are driving the tumorigenesis. However, recent
evidence suggests epigenetic plasticity is an alternative driving force
for the somatic evolution of tumors [37,38], and some novel
therapeutic strategies such as epigenetic treatments have emerged
[39]. Our results highlight that drug metabolism, microenvironment
and immune system modulation play a pivotal role in determination
of the robustness of cancer phenotype, and these modules have high
epigenetic instability in tumor cells. Given the high connectivity of
these gatekeeper modules, it is a reasonable inference that tumor
cells could exploit the epigenetic plasticity within these key modules
and thus gain a drug resistance phenotype, as suggested by the
‘phenotypic plasticity’ hypothesis [26] and the ‘epigenetic progenitor
model’ of cancer [25].
The potential strategy that tumors could exploit against the drug
treatment cannot be fully determined by etiology studies, but in silico
systems biology modeling will provide a way to predict the survival
strategies of a tumor when undergoing drug treatment. The task
presented here mainly aims to identify the central players in the
determination of the robustness of a cancer network, which is only
the first step in using systems biology modeling in the battle against
cancer. The next step will be behavior simulation based on this
network. We believe that the next generation therapeutics might
represent a paradigm shift from ‘etiology-based strategy’ towards
‘prediction-based strategy’ against the tumor. The former paradigm
relies on the comprehensive understanding of tumor history, but the
latter requires precise prediction of the tumor survival strategy
under therapeutic interventions. Systems biology modeling such as
we have presented in this study will enable this paradigm shift and
make a unique contribution to this continually evolving challenge.
Methods
Construction of gene modules
A gene module was defined as a group of genes which share a
similar function or regulation mechanism. The following types of
information were used to construct gene modules: (1) Protein sub-
network Data. In a protein-protein interaction network, nodes
represent proteins and edges represent a physical protein
interaction. A protein sub-network was defined by querying the
nearest neighborhood nodes of high connectivity nodes (hubs,
degree.=20), and named according to the gene name of the hub
protein. The human protein-protein interaction dataset in the
HPRD (human protein reference database, www.hprd.org, Sep 1,
2007 release) was used as the source dataset. (2) Gene sets which
share a common functionality in the gene annotation database.
Here all three categories in the Gene Ontology were used:
Biological Process, Molecular Function and Cellular Component
(geneontology.org). The Entrez Gene ID to Gene Ontology
mapping was downloaded from http://www.biomart.org. All
genes associated with one GO term was defined as one gene
module and the module was named according to the name/title of
GO terms. (3) Pathway Data. Genes in one KEGG pathway
(www.genome.jp/kegg) formed a gene module. (4) Protein
complex data. Genes in one protein complex formed a gene
module. The CORUM database [40](http://mips.gsf.de/genre/
proj/corum/index.html) was used as the source dataset. (5)
MicroRNA data. Genes regulated by the same microRNA formed
one gene module (where predicted target genes of the microRNAs
were taken from miRBase, http://www.ebi.ac.uk/enright-srv/
microcosm/htdocs/targets/v5/, target gene set version 5).
Because of the hierarchical structure of the ontology tree, the
parent nodes (gene modules) in ontology hierarchy might inherit
SINs from their children nodes (gene modules). To ensure the
specificity of inter-module interaction, we control the gene module
size and only gene modules containing between 100 and 200
genes were selected.
Generation of compound sensitivity gene signatures
Biological response and gene expression data from the NCI/
NIH Developmental Therapeutics Program In Vitro Cell Line
Screening Project [20] (http://dtp.nci.nih.gov) was used to
determine gene signatures for a series of compounds. The project
screens test compounds against a panel of 60 cell lines and for each
compound measures: (i) a biological response pattern (i.e., the
GI50 value, the compound concentration that causes 50% cell
growth inhibition) which is represented by a Response matrix R
(compounds 6 cell lines); and (ii) the baseline gene expression
profile for each compound for each of the 60 cell lines which is
represented by a gene expression matrix G (genes6cell lines). For
each compound, the Pearson Correlation Coefficients (PCC)
between the GI50 pattern across 60 cell lines and each gene
expression pattern across 60 cell lines were calculated [21], and
genes with a PCC P-value,0.05 were selected as the compound
sensitivity associated genes. The effects of other p-values were also
examined but were not found to have much effect on the results
(Table S1).
Construction of inter-module cooperation networks from
prognosis data
(1) Identification of query modules. Over-represented gene
modules in genes interrogated in the NCI 60 project (gene
expression matrix G) were detected by a fitting to a hypergeo-
metric distribution (see Supporting Text S1 for details). These
identified modules were then used as query modules (Figure 1c,
A1; Figure 1e, A1) to search for cooperative modules to form a
2-character header indicating the gene module definition source, PN: protein subnetwork; PA: pathway; BP: Gene Ontology biological process; MF:
Gene Ontology molecular function; CC: Gene Ontology cellular component; MR: microRNA targets.
doi:10.1371/journal.pone.0013937.g005
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Cooperative nodes;
(2) Identification of cooperative modules and creation of
Disease-specific inter-module cooperation network. Cooperative
modules were identified from prognosis data, which comprised
microarray gene expression data generated from cancer patients
and a prognosis that was classified as either good outcome (longer
survival time) or bad outcome (shorter survival time). Data sets
were analyzed for lung cancer [41], breast cancer [42], ovarian
cancer [43] and leukemia (AML) [44] (Supporting Text S1). For
each module in the query set from (1), we scanned the prognosis
data to identify synergistic gene partner, resulting in a synergistic
gene list. Synergistic partners were identified using an information
theoretic measure of synergy based on the patient microarray
expression data and the prognosis outcome [45] (Supporting
Text S1). Over-represented gene modules in this synergy gene list
were identified by fitting to a hypergeometric distribution,
resulting a list of gene modules (Figure 1c, B1; Figure 1e,
B1). For each cancer dataset, this produced a Disease-specific
Inter-Module Cooperation Network (IMCN) consisting of Query
and Cooperative nodes with edges running from Query nodes to
Cooperative nodes (Figure 1e).
(3) Perturbation modules and Pattern of Action (POA): In order
to investigate the effect of a drug compound on a IMCN we
generated an associated Pattern of Action (POA) for each
compound. This was done by selecting modules identified in the
previous step that were associated with the compound and
overlaying them on the disease-specific IMCN (Figure 1f).
Compound Pattern of Action map and the definition of
perturbation index
To quantify the compound ‘Pattern of Action’ we defined a
perturbation index that was defined in terms of the number of
compound gene ‘hits’ on modules within the IMCN. Compound
gene ‘hits’ were defined as the genes which were significantly
correlated with compound sensitivity across 60 cell lines. If at least
one gene within a module (node in IMCN) is hit by the compound,
this module is said to be hit by the compound. The perturbation
index (PI) of a compound c was defined as
PI c ðÞ ~
PN
i~1 Hi|Li ðÞ
Gc ðÞ
where N is the number of gatekeeper modules. For each
gatekeeper module, Hi is the number of gene hits by compound
c and Li is the number of active links, where a link is formed when
both source node and target node are hit by compound c. The
index is normalized by the total number of gene hits by the
compound: G(c).
Bootstrapping-based assessment of ability of
perturbation index to discriminate successful drugs from
the candidate pool
To investigate whether the Perturbation Index could be used
to identify successful drugs from a broader range of compounds,
a Drug Candidate set C was downloaded from the NCI Stan-
dard Agent Database (http://www.dtp.nci.nih.gov/docs/cancer/
searches/standard_agent.html); a set S of successful lung cancer
drugs were identified from a review paper [46], and overlapped
with C. The perturbation index was then calculated for each entry
in C and S. To test the significance of the differences in the PI
distributions for S and C we utilized a bootstrap based method
(with replacement). Given there are n compounds in S,w e
generated the background distribution by sampling n compounds
20000 times from candidate pool C, and calculated the average of
the perturbation index. Then we calculated the p-value based on
the number of times the average index of the candidate pool was
larger than the index for set S.
Quantification of drug combination synergy
To examine the effects of combined drug treatment, the drug
list was expand to include both approved lung cancer drugs (set S,
from review paper [46]) and new molecularly targeted drugs in
clinical development (from review paper [47]), and overlapped
with screened compounds in NCI 60 cell lines screening project.
All possible pairwise combinations of compounds in this combined
list were investigated. For each combination of two compounds,
the union of sensitivity associated gene lists of the two compounds
was formed and the perturbation index of each drug combination
was calculated in the same way as the individual compound.
Determination of genetic and epigenetic aberration
frequency in inter-module network
It has been proposed that events such as DNA mutation and
CpG methylation may play an important role in cancer. Thus,
genes that were highly represented in the IMCNs were identified
and then inspected to see their frequency characteristics of
mutation and methylation events.
(1) Identification of highly represented genes in gatekeeper and
checkpoint modules
As the gene modules were created from relationships defined in
ontologies, protein interaction networks, pathways and miRNA
targets, individual genes will, in general, be present in multiple gene
modules. Therefore, the number of times each gene appeared in
checkpoint modules and gatekeeper modules, respectively, was
calculated and two sets of the 10% and 20% most frequently
occurringgeneswereselectedasrepresentativegenes.Thisproduced
1230 representative genes for checkpoint modules and 183 genes for
gatekeeper modules for a 10% cutoff; and 2461 genes for checkpoint
modules, 366 genes for gatekeeper modules for a 20% cutoff.
(2) Gene-level somatic mutation and DNA methylation data
Somatic mutation data was obtained from the Sanger Institute
Catalogue Of Somatic Mutations In Cancer web site, http://
www.sanger.ac.uk/cosmic (version 42, May 28, 2009) [48].
Aberrant CpG methylation data in human tumours was obtained
from the ‘MethCancer DB’ web site, http://www.methcancerdb.
net (April 22, 2008) [49].
(3) Somatic mutation and DNA methylation incident rates
Incident rate of somatic mutations for each type of gene module
(gatekeeper and checkpoint) was defined as:
IRmut~
Xmut
N
Where Xmut is the number of mutated representative genes, and
N is the total number of representative genes.
Incident rate of aberrant CpG methylation (IRmet) for each type
of gene module was defined as:
IRmet~
Xmet
N
Where Xmet is the number of aberrantly methylated represen-
tative genes, and N is the total number of representative genes.
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from the checkpoint IRmut, a p-value was calculated according to
p~1{binocdf Xmut,N,Pmut ðÞ
Where binocdf is the Binomial cumulative distribution function,
Xmut is the number of mutated gatekeeper genes in the test set, N is
the total number of gatekeeper genes in the test set and Pmut is the
probability of a mutation event in checkpoint modules (equal to
the checkpoint IRmut).
The final two-sided p-value p2 was then calculated from
p2~2|min p,1{p ðÞ
where min returns the smaller of p or 1-p.
The p-value for methylation events in the gatekeeper and
checkpoint modules was calculated in the same manner.
Supporting Information
Text S1 Supplementary methods.
Found at: doi:10.1371/journal.pone.0013937.s001 (0.12 MB
DOC)
Table S1 The effect of drug-gene association P-value cutoff on
bootstrap result.
Found at: doi:10.1371/journal.pone.0013937.s002 (0.04 MB
DOC)
Figure S1 Gatekeeper gene modules in various type of cancer.
Found at: doi:10.1371/journal.pone.0013937.s003 (0.63 MB TIF)
Figure S2 Bootstrap results for pseudo index. To test whether
our results are biased by study bias introduced by gene module
definition, we defined a pseudo index for each compound =
Nnet/Ntotal, where Nnet is the number of gene hits in lung cancer
network for a given compound, and Ntotal is the number of genes
in the compound sensitivity-associated gene list. The same
bootstrap procedure (as demonstrated in Figure 4) run on this
pseudo index and result are demonstrated here. Blue line shows
background distribution and the red line shows the average pseudo
index of successful drugs. This figure clearly shows that this pseudo
index could not discriminate success drugs from candidate pool (P-
value.0.05).
Found at: doi:10.1371/journal.pone.0013937.s004 (0.45 MB TIF)
Figure S3 The effect of network size on perturbation index. This
figure shows that the number of network hits is proportional to the
overall number of compounds gene signatures (left), whereas the
perturbation index is independent of the number of compounds
gene signatures (right).
Found at: doi:10.1371/journal.pone.0013937.s005 (0.56 MB TIF)
Figure S4 The effect of gene module size on bootstrap results
(gene module size from 50–100 genes/modules, 24 gatekeeper
modules). In the main text we only selected modules which
contained 100–200 genes. To test whether our results were
sensitive to gene module size, we investigated the bootstrap results
(Figure 4c–4f in main text) when we changed the gene module
size. We investigated ranges 50–100, 50–200, 50–300, 50–400,
50–500, 50–600 (Figures S4–S9). In line with result demonstrated
in Figure 4c–4f, the bootstrapped P-values of the perturbation
index (top left plot in each figure) are always smaller (better) than
the modified perturbation index definition (as control, bottom left
of each plot).This plot shows bootstrap results for evaluating if the
average Perturbation index (PI) of successful drugs against lung
cancer (NSCLC) is significantly different from the candidate
compounds (see Methods). The meaning of each subplot is exactly
the same with Figure 4c–4f. Blue line shows background
distribution and the red line shows the average PI of successful
drugs. Top-left: the bootstrap result by using defined PI. We also
considered modified PI definitions and investigated their effect/
contribution on the performance of PI. These modifications
include: top-right: result from pseudo PI definition by using
checkpoint modules information to replace gatekeeper modules
information, bottom-left: result from pseudo PI definition by using
gatekeeper modules hits; bottom-right: result from pseudo PI
definition by using checkpoint modules hits.
Found at: doi:10.1371/journal.pone.0013937.s006 (0.75 MB TIF)
Figure S5 The effect of gene module size on bootstrap results
(gene module size from 50–200 genes/modules, 44 gatekeeper
modules). See Figure S4 for details.
Found at: doi:10.1371/journal.pone.0013937.s007 (0.72 MB TIF)
Figure S6 The effect of gene module size on bootstrap results
(gene module size from 50–300 genes/modules, 57 gatekeeper
modules). See Figure S4 for details.
Found at: doi:10.1371/journal.pone.0013937.s008 (0.71 MB TIF)
Figure S7 The effect of gene module size on bootstrap results
(gene module size from 50–400 genes/modules, 60 gatekeeper
modules). See Figure S4 for details.
Found at: doi:10.1371/journal.pone.0013937.s009 (0.71 MB TIF)
Figure S8 The effect of gene module size on bootstrap results
(gene module size from 50–500 genes/modules, 64 gatekeeper
modules). See Figure S4 for details.
Found at: doi:10.1371/journal.pone.0013937.s010 (0.71 MB TIF)
Figure S9 The effect of gene module size on bootstrap results
(gene module size from 50–600 genes/modules, 72 gatekeeper
modules). See Figure S4 for details.
Found at: doi:10.1371/journal.pone.0013937.s011 (0.71 MB TIF)
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